Atrial fibrillation destroys cardiac function.
Current treatments control the rhythm.
None restore the pump.

MaxWell Biomedical is developing the first device-based therapy designed to restore both sinus rhythm and atrial mechanical function — without tissue destruction.

The Unmet Need

AF is increasingly understood not as a purely electrical disorder, but as a progressive disease of atrial structure and function. As the atrium remodels, coordinated atrial contraction is lost — and with it, the "atrial kick" that contributes meaningfully to ventricular filling and cardiac output.

Restoring sinus rhythm on an ECG is not the same as restoring hemodynamics.

Pharmacologic therapies manage rate or rhythm without addressing atrial mechanics. Ablative approaches reduce arrhythmia burden but are fundamentally rhythm control strategies for symptom relief — they do not restore atrial pump function, and may come at the cost of atrial tissue integrity.

The result: atrial dysfunction persists, cardiac output remains compromised, and the underlying disease progresses.

No device today is designed to restore both atrial rhythm and atrial mechanical function.

CRT-A™, powered by the Rhythm360™ system, introduces a new class of cardiac resynchronization therapy — applied to the atrium.
Drawing on the same principle that transformed outcomes in ventricular heart failure, CRT-A is designed to synchronize atrial activation, stabilize rhythm, and maintain atrial transport function through an imperceptible, non-destructive, physiology-guided approach.

Two large patient populations with no adequate device solution today stand to benefit most: patients who develop AF following open-heart surgery, and patients living with AF and heart failure with preserved ejection fraction (HFpEF).